The study retrospectively analyzed clinical data from 113 prostate cancer patients treated at the UCLA Jonsson Comprehensive Cancer Center. All participants underwent PSMA PET/CT scans for recurrent disease evaluation, revealing critical insights about the anatomical extent and biological behavior of residual or metastatic lesions. PSMA PET/CT, by targeting membrane antigen expression on prostate cancer cells, provides superior sensitivity and specificity over conventional imaging, enabling early detection even at low PSA levels. This molecular imaging modality has rapidly become a vital tool for pinpointing occult disease sites post-prostatectomy and determining appropriate salvage therapy strategies.

Findings indicated that patients with no visible disease on PSMA PET/CT (classified as T0N0M0) experienced the most favorable progression-free survival. For this subgroup, whole-pelvis radiotherapy (WPRT) did not show significant benefits beyond prostate bed radiotherapy alone, suggesting that extensive radiation fields might be unnecessary when imaging reveals no overt disease. This emphasizes the potential to minimize overtreatment and associated toxicities by leveraging precise imaging.

Conversely, individuals with local, visible recurrence confined to the prostate bed (TrN0M0) demonstrated significant PFS improvement when treated with WPRT compared to prostate bed radiotherapy alone. This highlights the importance of incorporating imaging evidence of localized recurrence into radiation planning, supporting more aggressive therapy aimed at controlling subclinical micrometastases within the pelvic lymphatic drainage region. Such data underscore the principle that therapeutic volumes should be modulated based on anatomically accurate tumor burden assessment.

In cases where PSMA PET/CT revealed nodal or distant metastatic disease, the addition of androgen deprivation therapy (ADT) correlated with notably better PFS outcomes. ADT—a cornerstone systemic therapy targeting androgen receptor signaling—appears especially critical in controlling biologically aggressive and disseminated prostate cancer identified by advanced imaging. This multidimensional strategy combining imaging-guided radiotherapy with systemic hormonal therapy exemplifies personalized oncology, maximizing efficacy while potentially sparing patients from unnecessary toxicity.

John Nikitas, MD, the study’s lead investigator from UCLA, emphasized that routine utilization of PSMA PET/CT scans following biochemical recurrence provides clinicians with indispensable data that frequently alter treatment recommendations. In contrast to PSA levels alone, which were not strongly predictive of response to salvage therapies, PET/CT imaging delineates disease distribution and guides decisions that influence long-term outcomes. His remarks underscore the paradigm shift from relying solely on serum biomarkers toward integrated molecular imaging in prostate cancer care.

Beyond survival metrics, the study suggests that PSMA PET/CT can spare patients from the side effects of overly aggressive or inappropriate therapies. By objectively stratifying recurrent disease patterns—ranging from absent to localized versus metastatic—clinicians can select treatment intensities that provide optimal therapeutic gain without excessive morbidity. This precision approach enhances quality of life for men undergoing salvage therapy.

E. Christopher Dee, MD, from Memorial Sloan Kettering Cancer Center, who was not involved in the study, commented on the transformative potential of PSMA PET imaging. He pointed out that this technology enables a shift from one-size-fits-all radiation regimens to personalized treatments informed by anatomy and tumor biology. He highlighted that detecting cancer locations even at low PSA levels can fundamentally change practice patterns and improve patient outcomes. His insights further validate the clinical value of integrating functional molecular imaging into secondary and salvage prostate cancer management.

This research opens new avenues for prospective clinical trials aimed at refining the synergistic roles of imaging, radiotherapy, and systemic treatments in the salvage setting. The ability to visualize occult disease burdens non-invasively offers opportunities to test novel therapeutic combinations and dosing regimens with unprecedented precision and adaptive strategies aligned to changing tumor landscapes detected by PSMA PET/CT.

Furthermore, the adoption of PSMA PET/CT has implications beyond improved clinical outcomes. It promotes cost-effectiveness by avoiding unnecessary treatments and associated complications, thereby potentially reducing healthcare system burdens. The enhanced accuracy in staging and treatment response monitoring also contributes to more efficient resource allocation in oncology care.

Mechanistically, PSMA PET/CT imaging capitalizes on the overexpression of PSMA on prostate cancer cells and near absence in most normal tissues, generating high tumor-to-background contrast. Coupled with hybrid PET/CT technology, it allows simultaneous anatomical localization and molecular characterization, surpassing conventional imaging modalities such as bone scans or CT alone. This dual modality approach provides comprehensive insights that inform clinical decision-making with unparalleled granularity.

Overall, this study marks a significant milestone in the journey toward precision oncology for prostate cancer recurrence. It exemplifies how integrating molecular imaging with conventional treatment paradigms can tailor interventions to individual disease biology and distribution, ultimately enhancing patient outcomes and quality of life. As PSMA PET/CT becomes more widely accessible, its impact on guiding salvage radiotherapy and systemic treatment strategies is poised to expand exponentially, fostering more personalized, effective, and less toxic prostate cancer care worldwide.

Subject of Research: Prostate cancer patients with biochemical recurrence after radical prostatectomy

Article Title: Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy

News Publication Date: February 9, 2026

Web References:

• Full article and commentary available at JNCCN.org
• Commentary titled “The Last Word” at JNCCN.org

Image Credits: Credit to NCCN

Keywords: Prostate cancer, PSMA PET/CT, salvage radiotherapy, biochemical recurrence, androgen deprivation therapy, progression-free survival, molecular imaging, personalized oncology, radiation therapy, prostate-specific antigen, metastatic disease, precision medicine

Endometrial intraepithelial neoplasia represents a precancerous condition characterized by cellular atypia within the endometrial lining. However, a significant proportion of patients diagnosed with EIN harbor concurrent occult endometrial carcinoma, which is often only discovered upon postoperative histopathological examination. This diagnostic uncertainty challenges surgeons in planning the extent and aggressiveness of operative management, especially when considering the risks and benefits of performing lymphadenectomy or sentinel lymph node biopsy.

The study analyzed a cohort of 172 patients treated between June 2020 and December 2024 by gynecologic oncology surgeons. These individuals had been preoperatively diagnosed with EIN and subsequently underwent hysterectomy. Comprehensive clinical data—including demographic characteristics, imaging evaluations, intraoperative findings, and detailed pathology reports—were meticulously compiled for statistical analysis. The primary objective was to discern variables correlating significantly with the presence of hidden endometrial carcinoma.

Among the pivotal findings, age emerged as a formidable predictor. Patients aged 50 years and above demonstrated nearly a fourfold increased odds (OR = 3.94) of harboring endometrial carcinoma compared to younger counterparts. This age threshold aligns with the biological transition through menopause, implicating hormonal changes in carcinogenesis. Notably, postmenopausal status independently conveyed heightened risk, underscoring the complex interplay between endocrine milieu and endometrial cellular transformation.

Comorbidities such as diabetes mellitus and hypertension also revealed robust associations with occult endometrial carcinoma. The presence of diabetes doubled the likelihood (OR: 2.35), while hypertension increased it by approximately two and a half times (OR: 2.54). These conditions are often linked to metabolic syndrome, systemic inflammation, and vascular alterations, all of which may contribute to tumorigenesis in the endometrial microenvironment.

Body mass index (BMI), a modifiable clinical parameter, was found to be significantly related to cancer risk. A BMI of 35 kg/m² or greater was correlated with the presence of concurrent carcinoma, likely due to the influence of adipose tissue on estrogen production and chronic inflammatory signaling pathways. This finding reinforces the need for weight management strategies as part of comprehensive gynecologic cancer prevention efforts.

Endometrial thickness (ET), assessed through imaging modalities such as transvaginal ultrasound, served as a potent non-invasive marker. An ET measurement equal to or exceeding 14 millimeters quadrupled the odds (adjusted OR: 4.06) of detecting carcinoma upon pathological review. This metric offers clinicians a valuable diagnostic cue to augment preoperative risk stratification, potentially influencing the scope of surgical intervention.

The Mayo criteria, a well-established set of parameters guiding the necessity for lymph node dissection, were validated in this study cohort. Approximately 62% of patients who ultimately were diagnosed with endometrial carcinoma satisfied the criteria, indicating a substantial subset likely benefiting from lymph node assessment. Incorporating these criteria alongside the newly identified predictors may refine the selection process for LND, balancing oncologic thoroughness with surgical morbidity.

This research highlights the imperative for multidisciplinary collaboration between gynecologists, oncologists, radiologists, and pathologists in the preoperative evaluation of patients with EIN. By integrating clinical, metabolic, and imaging data, treatment plans can be better tailored to individual risk profiles. Such personalized approaches promise to optimize surgical outcomes while minimizing unnecessary procedures.

The implications extend beyond surgical planning; recognizing these predictors also opens avenues for enhanced screening and surveillance protocols. Patients exhibiting several of these risk factors may warrant intensified monitoring or even consideration of primary medical therapies. Conversely, low-risk individuals might avoid overtreatment, preserving reproductive potential and quality of life.

Technological advancements in imaging, coupled with novel biomarkers and molecular diagnostics, could further augment the predictive accuracy described in this study. Future investigations might explore the integration of genomic profiling with conventional risk factors, advancing precision medicine in gynecologic oncology.

Moreover, the study underscores the relevance of addressing modifiable lifestyle factors such as obesity and metabolic health in the broader landscape of endometrial cancer prevention. Public health initiatives targeting metabolic syndrome components could contribute to reducing disease burden at the population level.

In summary, the identification of age ≥50 years, postmenopausal status, diabetes, hypertension, BMI ≥35 kg/m², and endometrial thickness ≥14 mm as strong preoperative predictors marks a significant step forward. Patients exhibiting these parameters should be prioritized for referral to specialized gynecologic oncology services where comprehensive lymph node evaluation, including lymphadenectomy or sentinel lymph node biopsy, can be judiciously considered.

This evidence-based framework empowers clinicians to navigate the clinical dilemma inherent in EIN management, transforming surgical decision-making from reactive to proactive. Ultimately, it paves the way toward improved prognostication, individualized care, and better survival outcomes for women facing endometrial neoplastic disease.

Subject of Research: Preoperative predictors of endometrial carcinoma in patients with endometrial intraepithelial neoplasia undergoing hysterectomy.

Article Title: Preoperative predictors of endometrial carcinoma in patients undergoing hysterectomy for endometrial intraepithelial neoplasia.

Article References:
Çaltek, N.Ç., Çaltek, H.Ö., Yassa, M. et al. Preoperative predictors of endometrial carcinoma in patients undergoing hysterectomy for endometrial intraepithelial neoplasia. BMC Cancer 25, 883 (2025). https://doi.org/10.1186/s12885-025-14312-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14312-8